Stratification of Clinically Vulnerable People for COVID-19 Risk Using Antibody Testing (STARVINSKY)

Upcoming study
Expected to open 2023
This study is currently recruiting
Expected to close Spring 2025
This study is closed
This study closed in Spring 2025
We will update this page with study results when available.
Information on study results are included below
This study closed in Spring 2025

What next?

Original listing:

What next?

Original listing:

About this study

Although the COVID-19 vaccination program has proven very successful for most people, clinically vulnerable people, including those with pulmonary fibrosis, remain at a higher risk of COVID-19 despite having the vaccinations.  

Antibodies form an important part of the immune response which helps the body to fight infection. There is some evidence that this response to the vaccination is important for how effective the vaccination will be. It is not clear whether this is true in all clinically vulnerable groups and there appears to be variation between individuals with the same condition. There may be other factors that play a role, including other parts of the immune system, other health conditions, particular medicines, or features such as age.

This study aims to investigate which factor or combination of factors predicts an individual’s risk to COVID-19.

 – 

What is involved?

If you decide to take part in the study, there are two pathways you can choose from and the choice is entirely yours.

You can either:

  1. Attend 4 appointments face to face with your local clinical team at the hospital. If you choose to attend face to face appointments, you will have the option to either sign the online consent form or be consented at your first appointment with your local study team.

On each occasion you will be asked to provide:

• Blood samples

• Saliva test

• Nasal secretion test

OR

  1. You can join the study remotely. The central study team will send you a home sampling kit, called a dried blood spot, this allows you to prick your own finger and collect spots of blood.

For both pathways, you will be asked to provide your contact details (full address, contact number, NHS number if you know it, and GP information) to allow the researchers to check your medical and vaccination details.

During the study, you will be asked three times to fill in a questionnaire to understand whether your medical conditions or medications have changed and to check that you haven’t suffered a COVID-19 infection.

Throughout the study, you will be kept in contact with the study team about how the study is progressing, to see if you are happy with your ongoing participation in the study and to offer any support you need with the study.

Summary of involvement

Remote or face to face participation

Blood samples

Saliva and nasal secretions test

Questionnaires to understand your medical conditions and medications

Can I take part?

You may be able to take part if you have a medical condition, including pulmonary fibrosis, that increases your risk of developing a serious COVID-19 test.

In research studies, there are lots of different reasons why you may or may not be able to take part. These are known as inclusion and exclusion criteria (see list below). Only the clinical trial team will be able to fully determine whether you are able to take part in the study. You can withdraw at any point.

If you are not able to take part in this research study, there may be other opportunities for you to take part in different studies.

To find our more about other research opportunities visit our research finder main page.

You may be able to join this study if all of these apply:

People who have a health condition or take medication that can affect the functioning of their immune system. This includes people with pulmonary fibrosis.

You will not be able to join the study of any of the following applies:

Those who are unwilling to provide consent to take part.

What difference could taking part make?

The STRAVINSKY study will help to provide doctors, policymakers, and members of the public with up-to-date information on the impact of COVID-19 vaccinations for people with a wide range of different health conditions, including pulmonary fibrosis. It will help researchers to understand if antibody test results can predict an individual's risk of severe COVID-19 infection. The pulmonary fibrosis community have been significantly impacted by the COVID-19 pandemic and this study will help to understand more about the risk of infection.

Where does the study take place?

Study locations

Birmingham

Cardiff

Glasgow

Leicester

London

Oxford

Newcastle

Nottingham

Portsmouth

Sheffield

Southampton

You may still be able to take part in the study if you are not located near to one of the STRAVINSKY hospital sites, as there is a remote option for taking part from your home.

How to take part

If you would like to register your interest in taking part in the study, or if you have any questions, please contact the researcher by emailing stravinsky@contacts.bham.ac.uk

More information about the study can be found on the STRAVINSKY website.

Further information

The summary on this page provides information about an opportunity to participate in research. More detailed information about the study can be found via the following the links and through contacting the research team.

If you have any questions about this research study, please speak to your medical team and contact the researchers directly via:

stravinsky@contacts.bham.ac.uk

This study is supported by

University of Birmingham
Study ID number:

APF does not endorse or recommend any specific study. All responsibility for the study remains with the sponsors and investigators.

Every effort is made to keep these details up to date. If you are aware of any inaccuracies, please email research@actionpf.org